307 related articles for article (PubMed ID: 30506570)
21. Sorafenib for Egyptian patients with advanced hepatocellular carcinoma; single center experience.
Abdel-Rahman O; Abdelwahab M; Shaker M; Abdelwahab S; Elbassiony M; Ellithy M
J Egypt Natl Canc Inst; 2014 Mar; 26(1):9-13. PubMed ID: 24565677
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
Vilgrain V; Pereira H; Assenat E; Guiu B; Ilonca AD; Pageaux GP; Sibert A; Bouattour M; Lebtahi R; Allaham W; Barraud H; Laurent V; Mathias E; Bronowicki JP; Tasu JP; Perdrisot R; Silvain C; Gerolami R; Mundler O; Seitz JF; Vidal V; Aubé C; Oberti F; Couturier O; Brenot-Rossi I; Raoul JL; Sarran A; Costentin C; Itti E; Luciani A; Adam R; Lewin M; Samuel D; Ronot M; Dinut A; Castera L; Chatellier G;
Lancet Oncol; 2017 Dec; 18(12):1624-1636. PubMed ID: 29107679
[TBL] [Abstract][Full Text] [Related]
23. Survival of patients with advanced hepatocellular carcinoma: sorafenib versus other treatments.
Kim HY; Park JW; Nam BH; Kim HK; Choi JI; Kim TH; Kim HB; Kim CM
J Gastroenterol Hepatol; 2011 Nov; 26(11):1612-8. PubMed ID: 21517968
[TBL] [Abstract][Full Text] [Related]
24. Changes in the neutrophil-to-lymphocyte ratio predict the prognosis of patients with advanced hepatocellular carcinoma treated with sorafenib.
Hong YM; Yoon KT; Hwang TH; Heo J; Woo HY; Cho M
Eur J Gastroenterol Hepatol; 2019 Oct; 31(10):1250-1255. PubMed ID: 30925530
[TBL] [Abstract][Full Text] [Related]
25. pERK/pAkt phenotyping in circulating tumor cells as a biomarker for sorafenib efficacy in patients with advanced hepatocellular carcinoma.
Li J; Shi L; Zhang X; Sun B; Yang Y; Ge N; Liu H; Yang X; Chen L; Qian H; Wu M; Yin Z
Oncotarget; 2016 Jan; 7(3):2646-59. PubMed ID: 26544731
[TBL] [Abstract][Full Text] [Related]
26. Adoption of single agent anticancer therapy for advanced hepatocellular carcinoma and impact of facility type, insurance status, and income on survival: Analysis of the national cancer database 2004-2014.
Opneja A; Cioffi G; Alahmadi A; Jones N; Tang TY; Patil N; Bajor DL; Saltzman JN; Mohamed A; Selfridge E; Mangla A; Barnholtz-Sloan J; Lee RT
Cancer Med; 2021 Jul; 10(13):4397-4404. PubMed ID: 34060249
[TBL] [Abstract][Full Text] [Related]
27. The presence of vessels encapsulating tumor clusters is associated with an immunosuppressive tumor microenvironment in hepatocellular carcinoma.
Zhang P; Ono A; Fujii Y; Hayes CN; Tamura Y; Miura R; Shirane Y; Nakahara H; Yamauchi M; Uchikawa S; Uchida T; Teraoka Y; Fujino H; Nakahara T; Murakami E; Miki D; Kawaoka T; Okamoto W; Makokha GN; Imamura M; Arihiro K; Kobayashi T; Ohdan H; Fujita M; Nakagawa H; Chayama K; Aikata H
Int J Cancer; 2022 Dec; 151(12):2278-2290. PubMed ID: 36054900
[TBL] [Abstract][Full Text] [Related]
28. Vessels encapsulating tumor clusters: a novel efficacy predictor of hepatic arterial infusion chemotherapy in unresectable hepatocellular carcinoma.
Lin W; Lu L; Zheng R; Yuan S; Li S; Ling Y; Wei W; Guo R
J Cancer Res Clin Oncol; 2023 Dec; 149(19):17231-17239. PubMed ID: 37801135
[TBL] [Abstract][Full Text] [Related]
29. Serum cytokine profiles predict survival benefits in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective cohort study.
Hayashi T; Yamashita T; Terashima T; Suda T; Okada H; Asahina Y; Hayashi T; Hara Y; Nio K; Sunagozaka H; Takatori H; Arai K; Sakai Y; Yamashita T; Mizukoshi E; Honda M; Kaneko S
BMC Cancer; 2017 Dec; 17(1):870. PubMed ID: 29258450
[TBL] [Abstract][Full Text] [Related]
30. Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies.
Bruix J; Cheng AL; Meinhardt G; Nakajima K; De Sanctis Y; Llovet J
J Hepatol; 2017 Nov; 67(5):999-1008. PubMed ID: 28687477
[TBL] [Abstract][Full Text] [Related]
31. MicroRNAs miR-125b and miR-100 suppress metastasis of hepatocellular carcinoma by disrupting the formation of vessels that encapsulate tumour clusters.
Zhou HC; Fang JH; Shang LR; Zhang ZJ; Sang Y; Xu L; Yuan Y; Chen MS; Zheng L; Zhang Y; Zhuang SM
J Pathol; 2016 Dec; 240(4):450-460. PubMed ID: 27577856
[TBL] [Abstract][Full Text] [Related]
32. Prognostic factors of disease-free and overall survival in patients with hepatocellular carcinoma undergoing partial hepatectomy in curative intent.
Lurje G; Bednarsch J; Czigany Z; Amygdalos I; Meister F; Schöning W; Ulmer TF; Foerster M; Dejong C; Neumann UP
Langenbecks Arch Surg; 2018 Nov; 403(7):851-861. PubMed ID: 30267147
[TBL] [Abstract][Full Text] [Related]
33. Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Lyu N; Kong Y; Mu L; Lin Y; Li J; Liu Y; Zhang Z; Zheng L; Deng H; Li S; Xie Q; Guo R; Shi M; Xu L; Cai X; Wu P; Zhao M
J Hepatol; 2018 Jul; 69(1):60-69. PubMed ID: 29471013
[TBL] [Abstract][Full Text] [Related]
34. Epithelial-Mesenchymal Transition is Superior to Vessels-Encapsulate Tumor Cluster in Promoting Metastasis of Hepatocellular Carcinoma: a Morphological Evidence.
He C; Zhou Z; Jiang H; Yin Z; Meng S; Zhang J; Huang P; Xu K; Bian L; Xiao Z; Wang J
J Cancer; 2017; 8(1):39-47. PubMed ID: 28123596
[No Abstract] [Full Text] [Related]
35. MEP1A contributes to tumor progression and predicts poor clinical outcome in human hepatocellular carcinoma.
OuYang HY; Xu J; Luo J; Zou RH; Chen K; Le Y; Zhang YF; Wei W; Guo RP; Shi M
Hepatology; 2016 Apr; 63(4):1227-39. PubMed ID: 26660154
[TBL] [Abstract][Full Text] [Related]
36. Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with Sorafenib.
Oh CR; Kong SY; Im HS; Kim HJ; Kim MK; Yoon KA; Cho EH; Jang JH; Lee J; Kang J; Park SR; Ryoo BY
BMC Cancer; 2019 Apr; 19(1):292. PubMed ID: 30935424
[TBL] [Abstract][Full Text] [Related]
37. VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study.
Scartozzi M; Faloppi L; Svegliati Baroni G; Loretelli C; Piscaglia F; Iavarone M; Toniutto P; Fava G; De Minicis S; Mandolesi A; Bianconi M; Giampieri R; Granito A; Facchetti F; Bitetto D; Marinelli S; Venerandi L; Vavassori S; Gemini S; D'Errico A; Colombo M; Bolondi L; Bearzi I; Benedetti A; Cascinu S
Int J Cancer; 2014 Sep; 135(5):1247-56. PubMed ID: 24510746
[TBL] [Abstract][Full Text] [Related]
38. Comparison of treatment outcome between living donor liver transplantation and sorafenib for patients with hepatocellular carcinoma beyond the Milan criteria.
Cho Y; Lee JH; Lee DH; Cho EJ; Yu SJ; Yi NJ; Lee KW; Kim YJ; Yoon JH; Suh KS
Oncotarget; 2017 Jul; 8(29):47555-47564. PubMed ID: 28548930
[TBL] [Abstract][Full Text] [Related]
39. Lysyl Oxidase Is Predictive of Unfavorable Outcomes and Essential for Regulation of Vascular Endothelial Growth Factor in Hepatocellular Carcinoma.
Zhu J; Huang S; Wu G; Huang C; Li X; Chen Z; Zhao L; Zhao Y
Dig Dis Sci; 2015 Oct; 60(10):3019-31. PubMed ID: 26048020
[TBL] [Abstract][Full Text] [Related]
40. Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma.
Ricke J; Klümpen HJ; Amthauer H; Bargellini I; Bartenstein P; de Toni EN; Gasbarrini A; Pech M; Peck-Radosavljevic M; Popovič P; Rosmorduc O; Schott E; Seidensticker M; Verslype C; Sangro B; Malfertheiner P
J Hepatol; 2019 Dec; 71(6):1164-1174. PubMed ID: 31421157
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
